Kiniksa Pharmaceuticals International, Plc
(NASDAQ) KNSA
Kiniksa Pharmaceuticals International, Plc Financials at a Glance
Market Cap
$3.50B
Revenue (TTM)
$677.56M
Net Income (TTM)
$59.01M
EPS (TTM)
$0.75
P/E Ratio
61.38
Dividend
$0.00
Beta (Volatility)
0.82 (Low)
Dividend
$0.00
Beta (Volatility)
0.82 (Low)
Price
$45.75
Volume
25,809
Open
$46.76
Price
$45.75
Volume
25,809
Open
$46.76
Previous Close
$45.75
Daily Range
$45.45 - $46.79
52-Week Range
$18.25 - $49.12
Dividend
$0.00
Beta (Volatility)
0.82 (Low)
Price
$45.75
Volume
25,809
Open
$46.76
Previous Close
$45.75
Daily Range
$45.45 - $46.79
52-Week Range
$18.25 - $49.12
KNSA News
KNSA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Kiniksa Pharmaceuticals International, Plc
Industry
Biotechnology
Sector
Health CareEmployees
366
CEO
Sanj K. Patel
Website
www.kiniksa.comHeadquarters
Hamilton, HM 11, BM
KNSA Financials
Key Financial Metrics (TTM)
Gross Margin
55%
Operating Margin
11%
Net Income Margin
9%
Return on Equity
12%
Return on Capital
12%
Return on Assets
8%
Earnings Yield
1.63%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$3.50B
Shares Outstanding
76.54M
Volume
25.81K
Short Interest
0.00%
Avg. Volume
643.19K
Financials (TTM)
Gross Profit
$370.15M
Operating Income
$77.22M
EBITDA
$90.42M
Operating Cash Flow
$25.69M
Capital Expenditure
$277.00K
Free Cash Flow
$25.41M
Cash & ST Invst.
$414.07M
Total Debt
$9.50M
Kiniksa Pharmaceuticals International, Plc Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$202.13M
+65.0%
Gross Profit
$111.03M
+97.0%
Gross Margin
54.93%
N/A
Market Cap
$3.50B
N/A
Market Cap/Employee
$11.12M
N/A
Employees
315
N/A
Net Income
$14.20M
+259.8%
EBITDA
$23.74M
+243.2%
Quarterly Fundamentals
Net Cash
$404.58M
+73.1%
Accounts Receivable
$15.59M
-62.6%
Inventory
$54.90M
+108.2%
Long Term Debt
$6.51M
-17.2%
Short Term Debt
$2.99M
+49.9%
Return on Assets
7.73%
N/A
Return on Invested Capital
12.37%
N/A
Free Cash Flow
$53.26M
+186.7%
Operating Cash Flow
$53.89M
+187.1%